At 17 weeks, technosphere insulin was deemed noninferior to usual care, with the inhaled insulin group having an HbA1c of 7.6% vs. a 7.5% HbA1c for the usual care group (P = .01 for noninferiority).

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

[6,8,14] This method provides results that ... capD0-DBS results were closer to the predicted WB values for all evaluated HbA1c steps (4 %, 7 %, 7.5 %, and 10 %), and the prediction intervals ...